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Mycobacterium tuberculosis (Mtb) is a facultative intracellular pathogen and the second largest contrib-
utor to global mortality caused by an infectious agent after HIV. In infected host cells, Mtb is faced with a
harsh intracellular environment including hypoxia and the release of nitric oxide (NO) and carbon
monoxide (CO) by immune cells. Hypoxia, NO and CO induce a state of in vitro dormancy where Mtb
senses these gases via the DosS and DosT heme sensor kinase proteins, which in turn induce a set of ~47
genes, known as the Mtb Dos dormancy regulon. On the contrary, both iNOS and HO-1, which produce
NO and CO, respectively, have been shown to be important against mycobacterial disease progression. In
this review, we discuss the impact of O2, NO and CO on Mtb physiology and in host responses to Mtb
infection as well as the potential role of another major endogenous gas, hydrogen sulﬁde (H2S), in Mtb
pathogenesis.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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1.1. Global TB burden
The World Health Organization (WHO) has estimated that one-
third of the world’s population is infected with Mycobacterium
tuberculosis (Mtb), the bacterium that causes tuberculosis disease
(TB). In 2014, ~1.5 million people died from TB, making Mtb the
second deadliest pathogen of the 21st century after human im-
munodeﬁciency virus (HIV) [1]. HIV/AIDS exacerbates the global TB
burden, as is evidenced by that fact that of the 9.6 million people
newly infected in 2014, ~1.1 million (12%) were HIV positive [1].
Bacille Calmette-Guerin (BCG), the only vaccine against TB, is
effective only in children and does not provide consistent protec-
tion in vaccinated adults. TB can be treated with existing drugs;
however, the lengthy treatment regimen of 6e9months often leads
to patient noncompliance, which can result in the development of
drug-resistant TB. Globally, an estimated 5% of active TB cases are
multi-drug resistant TB (MDR-TB), deﬁned as resistance to isoniazid
and rifampicin, the two most potent ﬁrst-line anti-TB drugs. In
2013, an estimated 480,000 people worldwide developed MDR-TB,
of which an estimated 190,000 died [1,2]. Together with HIV
co-infection, the emergence of MDR-TB represents a growing
challenge to global public health that threatens to undermine the
gains achieved through the last 80 years of medical advances.
Clearly, it is of great importance to better understand the molecular
mechanisms ofMtb pathogenesis in order to developmore effective
drugs and therapies against this global threat.
1.2. Scope
In this review, we aim to provide a new perspective on the role
of gasotransmitters in TB, speciﬁcally nitric oxide (NO), carbon
monoxide (CO) and the newly emerging gas, hydrogen sulﬁde
(H2S). In addition, wewill discuss the role of molecular oxygen (O2),
including hypoxia, as the concentration of O2 plays a major role in
TB disease progression. An emphasis is placed on the in vivo sources
of these gases, and their roles in Mtb physiology and TB disease.
This is followed by discussion of the mechanisms whereby Mtb
senses and responds to these gases, including the Dos dormancy
three-component system, the more recently described SenX-RegX
two-component system, and iron-sulfur (Fe-S) cluster proteins.
This review will not attempt in-depth descriptions of the chemical
properties of these gases, but certain properties will be discussed
where appropriate. For in-depth reviews on the chemical proper-
ties of these gases, we refer the reader to several excellent review
articles [3e7]. This review will focus on the role of these host-
derived intracellular gases in regulating Mtb disease progression
with special focus on their speciﬁc roles in Mtb dormancy and in
regulating host immune responses against TB.1.3. Overview of Mtb physiology and disease dynamics
Mtb is a rod-shaped, acid-fast, obligate aerobewith awaxy lipid-
rich cell wall and extremely slow growth rate (doubling time of
~18 h in culture) [8]. Analysis of the Mtb genome has identiﬁed
dedicated machinery for lipid biosynthesis, numerous virulence
factors and sensor proteins that allow Mtb to respond to, and sur-
vive in, the hostile environment within host cells [9]. Mtb physi-
ology is unique as studies have shown thatMtb can survive for up to
12 years in sealed tubes and remain fully virulent [10]. During
infection Mtb is exposed to a wide range of host substrates
including organic acids, virtually all amino acids, nucleic acid pre-
cursors, nucleotides, lipids and numerous carbohydrates [11]. Thus,
it is clear that Mtb must adjust its metabolism in response to the
availability of environmental nutrients during the different stages
of infection.
Mtb infection typically begins with the inhalation of Mtb-con-
taining droplets aerosolized by an infected person [12]. The human
lung has a total alveolar surface area of ~70m2, and an adult inhales
and exhales ~11,500 L of air each day [13]. Since the only route of
Mtb transmission is by inhalation, the lungs are the primary site of
infection. The ﬁrst step of infection is the uptake of bacilli by
alveolar macrophages (AM) by phagocytosis and the formation of
phagosomes. Within the AM, fusion of phagosomes with acidic
lysosomes is critical for bactericidal activity [12]. However, Mtb
uniquely blocks phagolysosome fusion and acidiﬁcation, thereby
eliciting the rapid recruitment of neutrophils, inﬂammatory
monocytes, interstitial macrophages and T-cells in the lungs fol-
lowed by formation of cellular aggregates called granulomas.
Containment ofMtbwithin granulomas results in an asymptomatic
latent TB infection (LTBI), which is clinically deﬁned by a reactive TB
skin test without clinical symptoms of disease or radiological
ﬁndings [14]. Mtb granulomas have been shown to be hypoxic in
guinea pig and non-human primate (NHP) models and in a speciﬁc
mouse model of TB [15,16] (Fig. 1).
The occurrence of LTBI highlights a unique aspect of Mtb phys-
iology that has been extensively studied, but is not fully under-
stood; that is, the ability ofMtb to persist for years or decades in the
host in a genetically controlled state of low metabolic activity
referred to as dormancy [17]. As an obligate aerobe, Mtb requires
oxygen for growth, and therefore, it is rational to conclude that the
low oxygen environment of the TB granuloma contributes to this
metabolic shutdown of the bacillus. Studies in the 1950s showed
that open (oxygen rich) lesions from resected lung tissue from
human TB patients yielded actively growing Mtb that were pre-
dominantly drug resistant. In contrast, Mtb cells isolated from
closed (oxygen poor) lesions showed delayed growth, but were
drug sensitive despite being refractory to antimycobacterial drug
therapy [18,19]. This pointed to O2 as an important modulator of
Mtb physiology and therapeutic intervention. Not surprisingly, a
Fig. 1. Schematic overview of Mtb infection. Mtb infection is initiated when an individual is exposed to aerosolized bacteria. Of those exposed, ~70% remain uninfected, whereas
~30% develop primary infection. The host immune response to the primary infection is initiated by innate immune responses of macrophages and neutrophils via phagocytosis,
upregulation of iNOS and HO-1 and production of ROS/RNS. This is followed by antigen presentation by dendritic cells, cell-mediated immunity and further inﬁltration of immune
cells. These responses initially restrict bacterial replication and dissemination and lead to the formation of granulomas. In most cases, Mtb resides within the granuloma in a non-
replicating dormant state leading to LTBI. Approximately 90% of individuals with LTBI remain asymptomatic while ~5% develop active TB disease, characterized by massive he-
moptysis, dysregulated immune responses and extensive tissue damage.
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whereby Mtb persists in tissues for decades without replicating, to
then abruptly resume growth and cause disease. Acquiring such
knowledge will make a signiﬁcant contribution towards new
therapeutic interventions.
2. Role of oxygen in Mtb pathogenicity
2.1. Overview
Prior to the advent of TB drug therapy, patients were treated in
sanatoria, where rest and fresh air were considered conducive to
recovery [20]. The human host reaction to the bacillus was studied,
andwhile many patients succumbed to the consumptive process, in
other patients the bacilli were isolated and walled off by the body’s
defense mechanisms, leading to LTBI. One of the theories postu-
lated was that the lower oxygen levels in these “walled off” areas
inhibited the growth of the obligate aerobic mycobacterium, and
the concept of “resting the lung” while the infection took its course
became popularized. Various techniques to artiﬁcially collapse a
lung to render a relatively hypoxemic environment were then
proposed, and “collapse therapy” marked the birth of thoracic
surgery for the treatment of TB [21]. Methods of inducing “collapse
therapy” included instilling air, liquid or spherical objects into the
chest cavity to prevent the lung from completely expanding. By
depriving the organism of oxygen, it was thought that the disease
process would be curtailed. The advent of chemotherapy for TB
marked the end of an era of collapse therapy for TB, and the
attention of thoracic surgeons was then directed toward lungresection for TB (Fig. 2).
2.2. O2 gradients during Mtb infection
It was believed that patients with pulmonary TB improved if
they lived at altitudes above 2000 m due to the lower oxygen
tension [22]. Using radioisotope techniques, West and Dollery [22]
measured regional perfusion and ventilation and calculated oxygen
tension in the upright human lung. They observed that the partial
pressure of alveolar oxygen (PaO2) at sea level is approximately
132mmHg at the level of the ﬁrst anterior interspace, decreasing to
89 mm Hg at the level of the ﬁfth anterior [23]. These observations
supported the popular belief that oxygen tension is a major
determinant of the apical localization of pulmonary TB. However,
an alternate explanation is that the effect of gravity on the erect
human lung leads to a reduced pulmonary artery blood ﬂow in the
apical and subapical regions leading to higher O2 tension [24,25].
This reduced blood ﬂow would impede tissue clearance and favor
accumulation of Mtb, making the apical lobes ideal for Mtb growth
and proliferation [26]. Although it can be argued that conventional
in vitro tissue culture experiments expose Mtb to hyperoxic con-
ditions, recent in vitro studies have shown that the intracellular
environment ofMtb-infected primary humanmacrophages are also
hypoxic [27].
In the human TB lung, there is a gradient of oxygen tensions
from the upper apices to the lower lobes. The ﬂow rate of blood in
the upper apex of the lung is reduced due to depressed pressure
within the alveoli relative to pulmonary artery pressure in the
upright position. Therefore, the apices have elevated oxygen
Fig. 2. Typical chest radiograph, HRCT and granuloma of a TB patient. (A) Plain chest radiograph of a 46 year old woman with active pulmonary tuberculosis, demonstrating a
thick walled cavity in the right lung with associated parenchymal opaciﬁcation. (B, C) High resolution computed tomography (HRCT) images illustrate the location of the cavity in
the apical segment of the right lower lobe with the associated tree-in-bud appearance in the basal segments that are characteristic of active tuberculosis. (D, E, F) Right lower
lobectomy specimen with macroscopic features of active pulmonary tuberculous nodules with central caseous necrosis that is evident after sectioning. (G) Changes in partial oxygen
pressure (pO2) upon Mtb infection. (H) Representative tuberculous granuloma with central necrotic core surrounded by immune cells which create a gradient of O2, NO, CO and
possibly H2S.
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[28]. Several studies have shown that Mtb-infected lungs have
various oxygen tensions, all of which are below the normal range
seen in naïve subjects. This hypoxic environment within the Mtb-
infected lung has important implications for drug distribution and
bioavailability. The interplay between the host andMtb requires in-
depth analysis of various oxygen levels within the different com-
partments of human tuberculous lung, which could provide new
insights into the underlying mechanisms of current anti-TB drugs
activity. Despite recent progress, the physiology of Mtb-infected
lung tissue is not yet fully resolved in terms of drug penetration and
levels at the site of infection [29]. Animal models have been useful
for shedding light on the dynamics of granuloma formation and TB
disease progression. Granulomatous tissues in mouse models of TB
have features that resemble those in humans despite some subtle
differences [30]. Routine access to human tuberculous lung speci-
mens for research purposes is unfortunately restricted by the
paucity of these biopsies, and represents a major hindrance to TB
research. This is important as there is no single animal model that
accurately represents the full spectrum of human pulmonary TB.
Another limitation of human TB lung studies is that the granulomais dynamic in nature; hence real-time experimentation is not
possible in the human host. Mice, guinea pigs, rabbits, and non-
human primates have the ability to form well deﬁned granulomas
upon Mtb infection. Overall, it is clear that differential O2 concen-
trations play critical roles in the Mtb pathogenesis.2.3. Reactive oxygen species (ROS) and Mtb physiology
As a diffusible diatomic gas, O2 plays important roles in host
response to infection. As mentioned earlier, Mtb is exposed to low
O2 levels or hypoxic conditions within the lungs. Further, ROS and
reactive nitrogen species (RNS) generated by host immune cells
within the lung create a harsh intracellular environment against
Mtb. The oxidative burst created by NADPH oxidase (NOX) of host
phagocytic cells via catalysis of a single electron reduction of O2
generates O2─ and further reduction of onemore electron produces
hydrogen peroxide (H2O2) by the activity of superoxide dismutase
(SOD). Further, H2O2, in the presence of ferrous ions (Fe2þ) un-
dergoes the Fenton reaction to produce hydroxyl radical (OH).
Overall, hypoxia and these free radicals constitute a strong host
innate defense that can damage bacterial cell wall components,
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bacterial infections including Mtb [31e34]. Mice deﬁcient in the
cytosolic p47(phox) gene, which is required for O2─ production, are
susceptible to Mtb infection [35]. However, Mtb has evolved com-
plex mechanisms that provide protection from the damaging ef-
fects of ROS and hypoxia. Components of the Mtb cell wall,
including lipoarabinomannan (LAM), mycolic acids and phenolic
glycolic lipids (PGL-1), serve as effective ROS scavengers [36].
Mycothiol and recently discovered ergothioneine act as redox
buffers and protect Mtb from endogenous ROS [37,38]. Mtb also
possesses several ROS-scavenging gene products, which contribute
to ROS detoxiﬁcation and enhanceMtb survival. Mtb katG (catalase
peroxidase) decomposes H2O2 into water and oxygen thereby
protecting cells from the damaging effects of H2O2 [39].MtbMg/Fe
and Cu/Zn superoxide dismutases (sodA and sodC, respectively) also
protect the cells from oxidative burst and Mtb strains lacking these
genes are susceptible to ROS-mediated killing in both macrophages
in vitro and in the murine model of TB [40e42]. Other genes
including alkyl peroxide reductase genes (ahpC/D/E) and lipoamide
dehydrogenase (lpd) also contribute to Mtb survival against host-
generated ROS [43]. In response to hypoxic conditions generated
in the lung, the Mtb three-component heme sensor/regulator sys-
tem (DosS/R/T) senses and binds to host O2 thereby causing tran-
scriptional adaptation that results in upregulation of Mtb Dos
dormancy regulon genes, which enables bacteria to persist in a
non-replicative, low metabolic state [44] (see Section 6; Mtb gas
sensors).3. Nitric oxide
3.1. Overview
Since its initial characterization in the 1980s as a potent vaso-
dilator followed by its recognition as ‘molecule of the year’ in 1992
[45], the gasotransmitter NO has been found to regulate a wide
array of physiological functions such as neuromodulation, cellular
signaling, maintenance of redox homeostasis and as an effector
molecule during immune responses [46e49]. NO is produced
endogenously by the nitric oxide synthase (NOS) enzyme family via
NADPH- and O2-dependent oxidation of L-arginine to L-citrulline
and NO [50]. Three distinct mammalian NOS isoforms have been
identiﬁed based on the location of their expression: NOS enzymes
expressed by endothelial cells (eNOS, also referred to as NOS3) and
neurons (nNOS, also referred to as NOS1) are constitutively
expressed and act distinctively in response to intracellular calcium
levels in a calmodulin-dependent manner [51]. NO production for
immunological functions is mediated by a calcium-independent
inducible form, iNOS [51,52]. iNOS is expressed predominantly in
cells of myeloid lineage including macrophages and neutrophils
and is generally induced by redox stress, exposure to microbial
pathogens or bacterial endotoxins and pro-inﬂammatory cytokines
such as IL-1, IFN-g and TNFa (52). NO is amajor RNS and reacts with
atmospheric O2, superoxide anions (O2─), heme/non-heme iron
and thiol groups (-SH) of proteins to regulate a wide array of
cellular signaling responses. One such response includes formation
of peroxynitrite (ONOO─) upon reaction with O2─. NO and other
RNS including ONOO─ can modify bacterial DNA, proteins, and
lipids in host cells as well as in invading pathogens. Further, NO also
interacts with iron-sulfur clusters or heme groups of proteins. Ni-
trite and nitrate, which were thought to be end products of NO
metabolism, can be recycled to produce NO. Bacteria in the gut have
also been shown to form nitric oxide under varying physiological
concentrations of O2 and L-arginine via acidiﬁcation or reduction of
nitrite [53e55].3.2. Role of NO in host response to Mtb infection
Cells of the innate immune systems including macrophages and
neutrophils are crucial for host defense against many bacterial in-
fections including Mtb. One of their major anti-bacterial strategies
includes upregulation of iNOS expression and production of NO
[56e58]. Genetic knock-out studies with macrophages isolated
from NADPH oxidase- or iNOS-deﬁcient mice and in macrophages
isolated from TB patients provided early evidence that ROS
including O2─, and RNS including NO are important for host de-
fense against Mtb [35,59,60]. This was further substantiated by
MacMicking et al., who demonstrated that iNOS-deﬁcient mice are
highly susceptible toMtb infection and succumb to infectionwithin
~45 days post infection [61]. Blocking iNOS functionwith inhibitors
such as N6-(1-iminoethyl)-L-Lysine, aminoguanidine and NG-
monomethyl-L-arginine resulted in rapid bacterial growth,
increased disease pathology, high mortality and disease reac-
tivation in murine TB models [62e64]. Similarly, inhibition of the
iNOS-modulating cytokine TNFa also leads to Mtb reactivation in a
murinemodel of latent TB [65]. Amore recent study has shown that
NO regulates TB immunopathology and tissue damage by regu-
lating the levels of pro-inﬂammatory cytokine interleukin1b (IL1b)
in both IFNg-dependent and independent manners [66]. Compared
to murine models, the protective role of NO in Mtb-infected
humans is poorly understood. Nonetheless, immunohistochemical
analysis of human TB lung tissue and AM revealed the presence of
iNOS, NO, nitrotyrosine and increased exhaled NO in TB patients,
suggesting a role for NO in human TB [67e69]. Further, AM from
LTBI patients may kill Mtb in an iNOS-dependent manner [70,71].
Similarly, Rich et al. reported that inhibition of intracellular Mtb
growth correlated with elevated levels of NO and iNOS in AM
following Mtb infection [72]. Kuo et al. showed that increased NO
generation by AM of TB patients plays an autoregulatory role in
amplifying the synthesis of proinﬂammatory cytokines [73]. In the
human promyelocytic cell line HL-60, vitamin D3 treatment
resulted in signiﬁcant increase in NO production and enhanced
inhibition of Mtb growth [74]. NO is also thought to be important
for the formation of granulomas thereby protecting the host from
Mtb dissemination [75]. Interestingly, when peripheral blood
monocytes obtained from patients with active TB were infected
with Mtb in vitro, increases in both NO and TNF-a levels were
observed. However, the same cells obtained from patients with
MDR-TB produced little NO and TNF-a following Mtb infection,
suggesting a role for NO in TB-associated immunosuppression and
TB drug resistance [76]. Overall these studies clearly suggest that
NO plays signiﬁcant role in host response against Mtb.
3.3. Role of NO in Mtb physiology
As discussed above, iNOS/NO is an important component of the
host defense strategy against Mtb infection; however, Mtb has
developed a number of complex mechanisms to resist, subvert and
counter the damaging effects of intracellular NO and other RNS.
Darwin et al. have shown that the Mtb proteasome is crucial for
bacterial resistance against host-generated oxidative and nitro-
sative stress, likely through the degradation of stress-damaged
proteins [77]. Other studies showed that the noxR1 and noxR3
genes of Mtb confer protection against NO, RNS and ROS [78,79]
Further, Mtb ahpc was protective during RNS-induced necrosis,
apoptosis and also protected the bacterium from DNA damage by
detoxifying ONOO [80]. Interestingly, transcriptomic analysis of
iNOS-deﬁcient mice revealed that Mtb faces signiﬁcant oxidative
and nitrosative stress within the phagosomal environment. How-
ever, under these conditions Mtb undergoes drastic transcriptional
adaptation which enables the switch from aerobic to anaerobic
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nitrate is reduced byMtb to nitritewhich also assists in switching to
anaerobic respiration and inducing dormancy [82]. Similarly, ni-
trate respiration was also important for Mtb survival under acidic
and nitrosative stress environments [83]. Voskuil et al. showed that
non-toxic concentrations of NO inhibitMtb respiration and growth,
and result in the induction of Mtb dormancy regulon genes [84].
Similar to O2, NO is also sensed by the Mtb three-component sys-
tem DosS/R/T, which causes Mtb to enter dormancy in vitro
[44,85,86]. Interestingly, Cunningham-Bussel et al. have shown that
Mtb also produces signiﬁcant levels of nitrite during infection of
human macrophages, which assists its survival under hypoxic
conditions by modulating bacterial respiration, ATP consumption
and transcriptional modulation of stress associated genes [87].
Overall, these studies show that while NO is important for host
defense, Mtb has evolved potent NO-mitigating machinery (Fig. 3).
4. Carbon monoxide (CO)
4.1. Overview
While initially regarded as a toxic environmental gas, CO is now
known to be an enzymatic by-product of the heme oxygenase (HO)
system and a key intracellular messenger that regulates numerous
host physiological responses [5]. HO enzymes convert free heme,
sourced primarily from hemoglobin released from erythrocytes,
into CO, free iron (Fe2þ) and biliverdin in equimolar ratios [88]. Two
major HO enzymes have been characterized in mammals: the
inducible form, HO-1, and a constitutive isoform, HO-2.While HO-2
is constitutively expressed almost exclusively in the brain, HO-1 is
ubiquitously expressed at very low levels in almost all cell types,
but its expression is highly induced by cellular redox stress, hyp-
oxia, bacterial lipopolysaccharides andmany pathogenic challenges
including mycobacterial species [5,89]. The HO system produces
~86% of endogenous CO; the remainder is contributed by lipid
peroxidation, bacteria, photo-oxidation, and xenobioticFig. 3. Schematic illustration of the role of NO inMtb disease.Mtb infection upregulates t
NO. NO-mediated Mtb killing and modulation of host immune and inﬂammatory responses
O2─ to produce ONOO─ via NADPH oxidase. ONOO─ is pro-inﬂammatory, pro-oxidant and a p
and increased disease pathology. NO also plays important roles in Mtb physiology where it
response regulator DosR thereby inducing theMtb dormancy regulon. Also, NO can be conver
Mtb stress-associated genes.metabolism [5]. Verma et al. provided the ﬁrst evidence that CO has
a physiological role and, like NO, acts as a signaling molecule to
regulate cGMP production [90]. Additional studies showed CO to be
a key regulator of vascular and cardiac functions [91], inﬂammation
[92,93] and apoptosis [94,95]. Later studies revealed cytoprotective
roles for CO, which eventually lead to evaluation of CO as a thera-
peutic intervention in many pathophysiological conditions [96,97].4.2. Role of CO in bacterial pathogenesis
While the functions of CO in host responses to bacterial in-
fections have been studied, demonstration of a direct role for CO in
bacterial physiology has so far been limited to its bactericidal ac-
tivity in E. coli, Pseudomonas aeruginosa, and Staphylococcus aureus,
which results in death of the bacillus [98,99]. Roles for CO in bac-
terial pathogenesis have been shown in models of bacterial disease,
including sepsis and malaria [100]. Administration of a carbon
monoxide releasing molecule (CO-RM) resulted in enhanced bac-
terial clearance and improved outcomes in a HO-1-deﬁcient mouse
model of severe sepsis [101]. CO has also been shown to enhance
the rate of macrophage phagocytosis of E. coli through upregulation
of TLR-4 expression via p38 MAPK signaling [102]. A similar study
reported that macrophage-speciﬁc deletion of HO-1 increases
macrophage death upon infection with E. coli and E. faecalis and
that this effect was reversed by administration of exogenous CO
[103]. In malarial disease caused by the parasite Plasmodium,
Pamplona et al., have shown that pharmacological induction of HO-
1 or CO prevents experimental cerebral malaria (ECM) in mice by
inhibiting the release of free heme. This prevents disruption of the
blood brain barrier, and regulates CD8 T-cell responses [104].
Similarly, Jeney et al. demonstrated that the HO/CO system, along
with NO, provides disease tolerance during cerebral malaria via
suppression of T-cell responses [105]. Taken together, these studies
show that host-derived CO plays an important role in host defense
and bacterial physiology.he expression of iNOS, which catalyzes the conversion of L-arginine into L-citrulline and
are crucial for host protection against Mtb infection. On the other hand, NO reacts with
otent suppressor of T-cell responses and its overproduction leads to host tissue damage
is sensed by the Mtb heme sensor kinase proteins DosS and DosT, which activate the
ted to NO2 ─ or NO3 ─, which arrestMtb growth and lead to transcriptional adaptation of
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One anti-bacterial strategy of host phagocytes is the upregula-
tion of HO-1 and the production of CO via HO-1 enzymatic activity.
However, unlike other bacterial pathogens, Mtb tolerates physio-
logical levels of CO due to its expression of a CO-resistance gene, cor
[106]. The ﬁrst major advancement in our understanding of a role
for CO in Mtb physiology came from studies showing that like O2
and NO, CO can independently bind to Mtb heme sensor kinase
proteins DosS and DosT as conﬁrmed by the formation of heme-
carbonyl species upon exposure to CO [44]. Further, exposure of
Mtb cells to CO-RM-derived CO or CO gas results in increased
expression of dosR, hspX and fdxA genes of the Mtb dormancy
regulon [44]. In vitro infection studies using macrophages isolated
fromwild-type and HO-1/ mice showed that physiological levels
of host-generated CO induce a transcriptional proﬁle of Mtb
dormancy-inducing genes comparable to that of NO. This tran-
scriptional regulation is speciﬁc to CO and not the other products of
HO-1 enzymatic activity [107,108]. These studies also demonstrated
that while induction of the dormancy regulon genes (discussed
later) by NO requires the activity of both heme sensor kinases DosS
and DosT, the binding of CO to DosS alone is sufﬁcient to induce the
Mtb dormancy regulon. These data demonstrate a direct role for CO
in initiation ofMtb dormancy, and that HO-1-derived CO and iNOS-
derived NO may act in synchrony or independently to determine
the outcome of infection.
We and others have shown showed that HO-1 levels are
signiﬁcantly increased in macrophages in vitro and in the lungs of
mice followingMtb infection [107,108]. In the infected lung, HO-1 is
upregulated in immune cells that surround granulomas, suggesting
that increased production of CO may be a host strategy to induce
dormancy and restrict bacterial dissemination [108]. While these
studies highlight the role of HO-1-derived CO inMtb dormancy, the
role of CO in active TB disease is still unclear. Nonetheless, during
non-tuberculous infections (NTM) caused byMycobacterium avium
(M. avium), HO-1 confers host protection by suppressing the
expression of monocyte chemoattractant protein-1 (MCP-1) and
chemokine receptor 2 (CCR2) resulting in the formation of compact
granulomas, thereby reducing bacterial dissemination. HO-1 also
counteracts the cytotoxic effects of heme and inhibits apoptosis of
infected macrophages [109,110]. While based on a HO-1-deﬁcient
mouse model of M. avium infection, these studies did not demon-
strate a direct role for CO, a technically challenging task. However,
since CO is known to have anti-apoptotic, anti-inﬂammatory and
cytoprotective functions in macrophages when challenged with
bacterial lipopolysaccharide (LPS), it is reasonable to postulate that
the cytoprotective activity of HO-1 during M. avium infection is
attributable to CO [111]. Further, these studies point to HO-1 and CO
as potential targets for therapeutic interventions against M. avium
infection.
HO-1 and HO-1-derived CO play an important role in host anti-
inﬂammatory and anti-oxidative responses during various patho-
logical conditions [92,97]. Notably, active TB is characterized by
dysregulated inﬂammatory responses such as heightened immune
cell inﬁltration, increased levels of pro-inﬂammatory cytokines and
hemorrhagic inﬂammation resulting in hemoptysis and extensive
lung tissue damage [112e115]. Andrade et al. showed that HO-1
levels are signiﬁcantly elevated in the serum of patients with
active pulmonary TB compared to patients with LTBI, and suggested
that elevated HO-1 levels could be a potential TB biomarker [116]. A
later study by the same group showed that increases in HO-1 levels
in TB patients corresponded with decreased expression of matrix
metalloproteinase-1 (MMP-1), which drives immunopathology
during TB [117,118]. This inversely proportional expression of HO-1
and MMP-1 was speciﬁc to TB and was not observed in other lungdiseases. The authors also demonstrated that CO speciﬁcally re-
duces the expression of MMP-1 via suppression of c-Jun/AP-1
activation and suggests a potential therapeutic role for CO in host
protection against TB disease progression.
The dysregulated immune responses and increased inﬂux of
immune cells to the infection site during active TB results in sub-
stantial oxidative and nitrosative stresses that likely result in
extensive tissue damage. In contrast, dormant Mtb within granu-
loma remain non-pathogenic and drug insensitive, leading to LTBI.
These two disease phenotypes in TB are strikingly similar to ma-
laria, wherein a clinically latent pre-erythrocytic stage is required
to establish infection, and a subsequent erythrocytic stage is
responsible for active malarial disease [119]. Since application of
HO-1 and CO has been shown to protect mice frommalarial disease
pathology, a similar therapeutic strategy forMtb infectionmay have
merit.
Overall, while the role of CO in TB is not fully understood, it is
clear that it plays a key role in both controlling mycobacterial
dissemination and inducing dormancy in vitro. Further, as HO-1/CO
are important for host defense against oxidative and inﬂammatory
damage, their therapeutic application at the site of infection may
play a signiﬁcant role in minimizing exacerbated inﬂammation and
oxidative damage during TB (Fig. 4).
5. Hydrogen sulﬁde (H2S)
5.1. Overview
H2S has recently emerged as the fourth physiologically impor-
tant gas that mediates multiple processes in mammalian systems
including hypertension, atherosclerosis, heart failure, diabetes,
inﬂammation, neurodegenerative diseases and asthma [120e126].
H2S can be produced in the human body by resident microbes [127]
or by dedicated enzymatic machinery consisting of three inde-
pendent enzymes: cystathionine b-synthase (CBS), cystathionine g-
lyase (CSE) and 3-mercaptopyruvate sulfurtransferase (3-MST)
along with cysteine aminotransferase (CAT) [128] (Fig. 5). The
overall chemical properties of sulﬁde (deﬁned here as H2S þ HS)
relevant to biological systems are brieﬂy outlined below; further
details can be found in recent reviews on the biochemical proper-
ties of sulﬁde [6,129e131]. H2S is a weak acid, with a pKa of ca. 7 for
the dissociation H2S4 Hþ þ HS, the second pKa is high enough
that the sulﬁde anion (S2) almost certainly has no biological
relevance. This means approximately 28% of sulﬁde is present as
the protonated nonelectrolyte species (H2S, hydrogen sulﬁde) at pH
7.4. As an uncharged small lipophilic molecule, the fact that pro-
tonation/deprotonation is extremely rapid means that membranes
are quite permeable and so sulﬁde produced in one compartment
will rapidly distribute within the biological milieu. The volatility of
H2S also demands relatively rapid exit to a headspace, requiring
careful attention to experimental conﬁguration. The chemical
reactivity of sulﬁde is dominated by the fact that, like thiol, it is a
strong nucleophile, much more so in the hydrosulﬁde anion form
(HS) than H2S. This means that HS is the species that exerts the
majority of (but not all) biochemical reactivity. The nucleophilicity
of sulﬁde is reﬂected in its electronegativity, second only to oxygen
(except for ﬂuorine). Unlike oxygen, sulfur is able to utilize its 3d
orbitals for an expanded valence shell thereby allowing multiple
bonds and formal oxidation states ranging from 2 (e.g. H2S) to þ6
(e.g. SO42).
Being electrophiles, transition metal ions react with sulﬁde by
both complete (oxidation-reduction) and partial (bonding) electron
transfer. The product of oxidation-reduction is the reduced metal
and elemental sulfur (So). Elemental sulfur exists as a polymer, the
most common conﬁguration being S8. In the case of bonding, the
Fig. 5. Schematic illustration of endogenous H2S production and functions. H2S is produced endogenously by cystathionine-b-synthase (CBS), cystathionine-g-lyase (CSE) and 3-
mercaptopyruvate sulfurtransferase (3-MST). CBS and CSE use L-cysteine as the primary substrate with pyridoxal-50-phosphate as a cofactor. H2S formation through 3-MST is
downstream of cysteine aminotransferase (CAT), which catalyzes the reaction of L-cysteine with a-ketoglutarate leading to the formation of 3-mercaptopyruvate, the substrate used
by 3-MST to form H2S and pyruvate. H2S is important for numerous physiological responses including vasodilation, neuromodulation, and inﬂammation and can also act as an anti-
oxidant.
Fig. 4. Schematic illustration of endogenous CO production and role in Mtb disease. CO is produced by HO-1 via heme catabolism. Other products of this enzymatic reaction
include free iron (Fe2þ) and biliverdin, which is further converted into bilirubin. Iron further increases the expression of ferritin, an iron storage protein. CO, bilirubin and ferritin are
potent antioxidant molecules. Further, CO and bilirubin also play important roles in regulating inﬂammation, immune cell proliferation and host cell apoptosis. Mtb infection
induces HO-1 expression thereby increasing endogenous CO, which could protect against heme-mediated tissue damage via its anti-oxidative, anti-proliferative and anti-apoptotic
properties. CO binds to Mtb heme sensor kinase proteins DosS and DosT, which like NO, induce the Mtb dormancy regulon.
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bond. The toxicity of sulﬁde in humans is dominated by its re-
actions with metals, speciﬁcally, with mitochondrial cytochrome
oxidase at the site of O2 binding (the binuclear CuB/heme a3) and
with hemoglobin which, through the intermediacy of a high
valency heme-oxygen complex, produces sulfhemoglobin, which
contains a covalent heme modiﬁcation. Sulﬁde anion is also a key
component of a large class of iron proteins containing iron-sulfur
centers, which serves both oxidation/reduction and signaling
roles. Undoubtedly, the best studied biological system of metal-
sulﬁde interaction is in a symbiotic mollusk/bacterial symbiosis,
where cytoplasmic hemoglobin in the host delivers both O2 andsulﬁde to the bacterium for metabolism [132]. The properties of the
mollusk hemoglobin are elegantly tuned to carry these two mole-
cules, involving conﬁguration of the heme pocket and proximal and
distal protein residues.
Partially reduced oxygen species (O2─, H2O2, and HO) are also
electrophiles and react with sulﬁde. The rates of reaction, however,
are highly variable, and in vivo these reactions are not likely to be
important under most conditions due to the low concentrations of
these species and sulﬁde. Finally, sulﬁde also reacts with other
electrophilic species, of particular interest being the newly
discovered species 8-nitro-cyclic GMP [133]. There is evidence that
this reaction plays a key role in the signaling properties of this
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cies, for example, disulﬁde RSSR’. The product is thiol and persul-
ﬁde: HS þ RSSR’/ RSS þ R’S e (contrary to some statements in
the literature, sulﬁde does not react with thiol; in general, nucle-
ophiles do not react with other nucleophiles). Similar further re-
actions also produce polysulfur species R(S)nH, in great abundance.
This is true for both small thiols (e.g. glutathione) and also protein
cysteine thiol. Indeed, it may well be that these species are more
important functionally than sulﬁde itself. In spite of the lack of
relevant data, there are observations about the role of H2S in
mammals and other prokaryotes [127,134,135].
5.2. A role for H2S in TB?
It is not known whether H2S impacts the outcome of Mtb
infection and TB disease in humans. Regardless, the physicochem-
ical properties of H2S, as well as its established role in modulating
immunity point to a potentially important role for this gas in TB.
Both CBS and CSE have been found critical for proper alveolariza-
tion and functioning of the lung [136]. Since the human lung is the
primary organ of Mtb infection in which the bacillus can reside for
decades, it is reasonable to posit thatMtbmay havemechanisms for
sensing and responding to H2S. Also, since CBS and CSE play
essential roles in human health [136e138], it is plausible that H2S
via its immunomodulatory function is necessary for protection
against Mtb infection. Studies on the role of H2S on Mtb patho-
genesis are eagerly awaited.
However, there are observations on the role of H2S in mammals
and other prokaryotes that can be extrapolated to comment on the
possible role that H2Smay play in TB disease. For example, exposing
mice to low amounts of H2S induces a reversible hibernation-like
state characterized by lowering of body temperature, and reduced
energy expenditure in the form of reduced ATP consumption and
low metabolic rate (as evaluated by substantially decreased CO2
production and O2 consumption) [139]. Induction of this hypo-
metabolic state by H2S, referred to as suspended animation, is an
oxygen-dependent phenomenon [140]. It is believed that the in-
hibition of O2 utilization and induction of suspended animation in
low O2 conditions could have a host-protective role [140]. There are
parallels that can be drawn from this H2S-induced suspended an-
imation state and the characteristic features associated with
dormancy inMtb. For example, during dormancyMtb is exposed to
severe environmental stresses (e.g., low pH, O2 and carbon source
limitation) that induce a metabolic state characterized by
decreased respiration, low ATP levels, reduced growth, low O2
consumption and reduced metabolic rates.
H2S primarily affects mitochondrial respiration by targeting
complex IV of the respiratory chain, i.e., cytochrome c oxidase [141].
Based on historical studies using manometry [142] and in a more
recent drug study [143], Mtb is known to exhibit immense respi-
ratory ﬂexibility, which is a key requirement for maintaining an
intracellular pathogenic lifestyle. It possesses two proton-pumping
complexes: NADH dehydrogenase I, which is dispensable for
growth, and an aa3-type cytochrome c oxidase, which provides the
means of O2 reduction [144]. More importantly,Mtb also expresses
a high-afﬁnity alternate terminal oxidase, cytochrome bd oxidase,
that can partially compensate for the loss in activity of the bc1-aa3
complex [144]. Therefore, it will be of signiﬁcant interest to
determine whether H2S affects Mtb respiration and consequently
in vivo pathogenesis.
Lastly, there is a growing appreciation for the complex in-
teractions between different intracellular gases such as NO, CO and
H2S as they can all interact with the host (and potentially Mtb)
electron transport chain [145e150]. Furthermore, NO and CO can
also regulate H2S levels by targeting the CBS heme prosthetic group[151e153].
6. Mtb gas sensors
6.1. The Mtb Dos dormancy regulon
The success ofMtb as a pathogen is based in part on its ability to
enter into dormancy, a genetically and physiologically controlled
non-replicative state characterized by metabolic quiescence. In this
reversible state, Mtb can survive the harsh intracellular environ-
ment inside the host [154]. Of note, dormancy in Mtb is a physio-
logical state of persistence and should not be confused with TB
latency or LTBI, which are clinical descriptors indicating the
absence of TB disease symptoms in infected individuals. The tran-
sition into dormancy occurs via marked changes in gene expres-
sion, including up-regulation of the widely studied 47-gene Dos
regulon in response to CO, NO or hypoxia [155,156]. In addition to
the genes of the Dos regulon, other gene sets, such as the enduring
hypoxia response (EHR) genes, may play a role in dormancy;
however molecular mechanisms of their regulation are largely
unknown [157,158]. Transcriptional analysis under hypoxic condi-
tions in vitro revealed that even though ribosomal and metabolism
genes are downregulated under low-O2 conditions, the Dos regulon
genes are signiﬁcantly upregulated [159]. Similar to the response to
hypoxia or low O2 levels, other host-generated stresses such as CO
and NO also upregulate these dormancy regulon genes. While
many genes of this regulon are still being characterized, they are
predicted to be involved in modulating Mtb physiology. These
include genes with chaperone functions (acr or Rv2031c), ferre-
doxin modulation (fdxA or Rv2007c), nitrate/nitrite transporter
(nark2 or Rv 1737), ribonuclease reductase (nrdZ or Rv0570) and
triglyceride synthase (tgs1 or Rv3130) [19,160].
The genes of the dormancy regulon are upregulated when Mtb
senses host-generated hypoxia, NO and CO via the heme-
containing kinases DosS and DosT, which along with a single
response regulator, DosR, comprise the DosR/S/T three-component
system [44,107,161]. As discussed earlier, our studies and others
have shown that the redox or ligation status of the heme iron in
DosS and DosT modulates binding to O2, NO and CO either together
or independently. This shows that these host-generated intracel-
lular gases are central to Mtb disease progression [19,44]. This also
emphasizes the fact that the success of Mtb as a pathogen can be
largely attributed to its unique ability to sense and respond to NO,
CO or lowO2. Several lines of evidence point to these diatomic gases
as modulators of dormancy. Firstly, Mtb is an obligate aerobe that
requires oxygen as a terminal electron acceptor. However, the un-
canny ability ofMtb to survive for more than a decade in test tubes
without oxygen (or at least extremely low concentrations of oxy-
gen) points to a novel aspect of Mtb adaptation to low oxygen en-
vironments. Secondly, it has been conclusively demonstrated that
iNOS, and therefore NO, is crucial for protection of mice againstMtb
[61]. Further studies in patients with active pulmonary TB conﬁrm
the importance of NO in Mtb pathogenesis [35e76,162]. Unfortu-
nately, despite several elegant in vitro studies [107,108,163] a clearly
established role for either HO-1 or CO in Mtb pathogenesis has yet
to be demonstrated and represents an unexplored area of
investigation.
It should be noted that the lack of oxygen and the presence of
sufﬁcient levels of NO and/or CO inhibit Mtb respiration and ulti-
mately retard growth. An important difference between NO and CO
is that CO can only react with ferrous (Fe2þ) ironwhereas NO reacts
with Fe2þ and Fe3þ. This raises the obvious question as to how
concentration gradients of oxygen, NO and CO, as well as the
different afﬁnities of DosS and DosT for these gases contribute to
Mtb disease.
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performed in vitro or in mouse models of TB and their relevance to
human TB is yet to be established. However, recent studies in our
laboratory using tissue samples from freshly resected human
tuberculous lungs have clearly shown that signiﬁcant levels of ROS/
RNS are indeed present in human TB lungs. Interestingly ROS/RNS
levels were directly proportional to the extent of tissue damage,
suggesting a gradual disease progression.6.2. Mtb iron-sulfur (Fe-S) cluster proteins
Proteins that contain iron-sulfur cluster [Fe-S] prosthetic
groups are found in virtually all organisms and provide a mech-
anism for cells to sense changes in redox and respond to intra-
cellular gases. The Mtb WhiB family of proteins WhiB1 (Rv3219),
WhiB2 (Rv3260c), WhiB3 (Rv3416), WhiB4 (Rv3681c), WhiB5
(Rv0022c), WhiB6 (Rv3862c) and WhiB7 (Rv3197A)] contain four
cysteine residues arranged in a CyseX-14-22-Cys-X2-Cys-X5-Cys
motif, with the exception of WhiB5 [164]. Studies of homologs in
Streptomyces spp suggested that these proteins are Fe-S clusters
proteins [164]. Indeed, Mtb WhiB3 is a 4Fe-4S cluster protein that
maintains intracellular redox balance and responds to oxygen and
NO [165]. Recently, WhiB3 was shown to regulate the production
of a redox buffer, ergothioneine, which is critical forMtb virulence
and drug susceptibility [38]. The WhiB proteins likely acts as
redox sensors via their Fe-S clusters and are critical in maintaining
redox homeostasis, a key determinant of Mtb virulence [19,38].
The seven members of the Mtb WhiB family perform diverse
functions including cell division (WhiB2) [166], fatty acid meta-
bolism and pathogenesis (WhiB3) [165,167,168], oxidative stress
(WhiB6) [169,170] and antibiotic resistance (WhiB7) despite only
moderate sequence homology among themselves [171,172]
(Fig. 6).
Since the discovery of aWhiB-like protein in Streptomyces spp in
1992, a long-standing question has beenwhether these proteins are
DNA-binding proteins that regulate gene expression [173]. Nearly
20 years later, it was shown that Mtb WhiB3 binds DNA [168].
Important features of its DNA binding capacity, which wasFig. 6. Schematic overview of gasotransmitters in Mtb physiology. Mtb heme sensor k
response regulator DosR which induces the Mtb dormancy (Dos) regulon. SenX3 of the Sen
generated O2, NO and CO. Binding of O2 to SenX3 stimulates Mtb growth during reactivatio
effects downstream of SenX3. Further, interaction of O2 or NO with members of the WhiB fa
as well as metabolic adaptation under conditions of host-generated stress.extrapolated to other WhiB members, was that oxidized apo-
WhiB3 binds DNA much stronger than either holo-WhiB3 or
reduced apo-WhiB3. Subsequently, it was shown that Mtb apo-
WhiB1, apo-WhiB2 and apo-WHiBTM4 bind DNA strongly in
contrast to the holo-forms, which bind DNA weakly or not at all
[164]. These ﬁndings revealed that DNA binding and transcriptional
activity are modiﬁed by environmental conditions such as hypoxia,
free radicals such as NO and oxidative stressors that inﬂuence the
redox state of the 4Fe-4S cluster (of the holo-form) or the oxidation
states of the Cys residues (of the apo-form). Overall, it appears that
Mtb has evolved a sophisticated family of proteins that function as a
ﬂexible redox switch in response to oxido-reductive stress that
causes an imbalance in intracellular redox homeostasis.
Redox homeostasis in mycobacteria is distinct from other
intracellular pathogens as they lack a conventional glutathione
system and homologues of the prototype sensor proteins in other
intracellular pathogens such as SoxR, ArcAB, FNR and OxyR (a
pseudogene inMtb) [172e174]. Instead,Mtb uses two distinct redox
couples, mycothiol and ergothioneine, and harbors at least 50
proteins containing Fe-S clusters that facilitate an intercellular life
cycle [37,175]. Interestingly, Mtb has a higher incidence of Fe-S
cluster proteins (~6.5motifs/1000 ORFs) than other aerobic bacteria
(2.8 motifs/1000 ORFs), underscoring the importance of Fe-S clus-
ter proteins to pathogenic adaptations of Mtb [176,177].6.3. Other gas-sensing systems
Apart from DosS/R/T, Mtb has other heme sensor kinase and
response regulator protein systems that are predicted to play roles in
its metabolic adaptation, including the SenX3-RegX3 system and the
PhoPR systems [178,179]. Transcriptomic analysis of a senX3-regX3
knockout strain of Mtb showed downregulation of several DNA
repair and protein synthesis genes as well as genes important for
survival under hypoxic conditions such as cydB and gltA1 [180].
Further, this Mtb knockout strain fails to establish successful infec-
tion of macrophages in vitro and in guinea pig and murine models of
TB [181e183]. More recently, SenX3was shown to sense and bind O2,
NO and CO. Binding of O2 to SenX3 is associated with growthinase proteins DosS and DosT sense host-generated NO, CO and O2 and activate the
X3-RegX3 two-component system is a heme sensor kinase that also responds to host-
n; however, binding of CO or NO inhibits growth. RegX3 is presumed to mediate these
mily of iron-sulfur cluster proteins regulates the intracellular redox homeostasis of Mtb
K.C. Chinta et al. / Nitric Oxide 59 (2016) 28e4138stimulation during reactivation whereas binding of NO and CO to
SenX3 inhibits growth via inhibition of kinase activity [184] (Fig. 6).
7. Future challenges and conclusions
The development of highly effective therapeutic interventions
such as new antimycobacterial drugs and vaccines hinges on un-
derstanding themechanisms bywhichMtb can persist for decades in
the human lung to ultimately cause disease. Given the ubiquitous
nature of O2, NO, CO and H2S, it is not surprising that some of these
endogenous gases play critical roles in a wide range of pathophysi-
ological processes. The importance of these gases in human health is
underlined by genetic deﬁciency and polymorphism studies. For
example, the pathophysiological consequences of deﬁciencies in HO-
1 (systemic inﬂammation, intravascular hemolysis, asplenia,
vulnerability to stressful injury) [185,186], CBS, CSE or 3-MST (hyper-
homocysteinemia, mercaptolactate-cysteine disulﬁduria, mental
retardation and aggressive vascular disease, neuoroblastoma and
hepatoblastoma) [187e189] and iNOS (susceptibility to TB, and a
wide range of diseases) [190] have profound effects on human
health. Therefore, dysregulation of the levels of these gases at the site
of infection could lead to ineffective drug treatment or impair in-
ﬂammatory responses to exacerbate disease.
A practical advantage in studying the role of NO, CO and H2S in
Mtb infection is that mice with deﬁciencies in expression of iNOS,
HO-1, CBS, CSE and 3-MST are available for experimentation. To
conﬁrm the clinical relevance of these gases, ﬁndings from these
studies should be expanded to the analysis of human pulmonary TB
tissue samples. Unfortunately, a major impediment to these studies
is the paucity of freshly resected humanTB lung tissue. Of particular
interest would be to determine what cell populations in animal and
humanTB lung tissues express CBS, CSE, 3-MST, iNOS and HO-1, and
their respective levels. It is important to note that in the case of
iNOS and HO-1, which are expressed at the site of infection
[67,107,108], gradients of NO, CO and O2 are likely to exist in hypoxic
Mtb granulomas [19,191]. This presents an interesting opportunity
for studying crosstalk among the gases since CBS and iNOS contain
heme moieties, which represent potential interaction sites for NO,
CO and O2.
Another important albeit unexplored area of investigation is the
role of these gases in antimycobacterial drug susceptibility in vivo.
First considered for NO, it is tempting to speculate that gaso-
transmitters play a role in antimycobacterial drug efﬁcacy [67]. On
the other hand, since these gasotransmitters are ubiquitous, phar-
macologic modulation of gene expression or the application of
iNOS, HO-1, CBS, CSE or 3-MSTendproducts has long been proposed
as a therapeutic avenue based on model studies [3e7]. Under-
standing how Mtb directly interacts with these gases, their corre-
sponding targets, how these targets discriminate between these
gases, and the signaling responses induced by these gases will be of
substantial value. NO, CO and O2 have been shown to target the
heme irons of Mtb DosS and DosT. However, targets other than the
WhiB family proteins and the SenX3-RegX3 two-component sys-
tem also exist. Further, a detailed understanding of how these
gasotransmitters target the Mtb electron transport chain, which
contains numerous heme and Fe-S cluster prosthetic groups,
should provide new information on energy metabolism, and how
the bacillus is capable of surviving under harsh intracellular con-
ditions including hypoxia and gradients of NO, CO and H2S. TheMtb
electron transport chain is remarkably plastic and capable of
rapidly re-routing electrons around speciﬁc inhibition by switching
between terminal oxidases. Despite the many potential targets,
very little is known about this ATP-generating pathway in Mtb.
Many provocative questions can emerge from such studies. For
example, do these gasotransmitters inhibits or stimulaterespiration, and do they have a predominantly bactericidal or
bacteriostatic effect on Mtb?
In conclusion, it is anticipated that as more is learned about how
these gasotransmitters regulate host immunity and directly targets
Mtb, many new avenues of research will open up, compelling re-
searchers to reassess existing paradigms forMtb persistence, and to
seek new testable hypothesis.
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